Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
MHLW OKs First Generics for Tracleer, 6 Other APIs towards December Listing
The Ministry of Health, Labor and Welfare (MHLW) on August 15 approved first generics for seven active pharmaceutical ingredients (APIs) towards their reimbursement listing in December, including those for Actelion Pharmaceuticals’ pulmonary arterial hypertension (PAH) drug Tracleer (bosentan). Tracleer is…
To read the full story
Related Article
- Talion AG, 2 Other APIs Skip December Gx Listing
December 8, 2016
- First Generics for 5 APIs to Join NHI Price List on Dec. 9
December 8, 2016
- Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
- Kipres/Singulair to Face Generic Onslaught in Dec.; Competition to Hit Tracleer, Too
August 4, 2016
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…